Darunavir
- Generic Name
- Darunavir
- Brand Names
- Prezcobix, Prezista, Rezolsta, Darunavir Viatris (previously Darunavir Mylan), Darunavir Krka
- Drug Type
- Small Molecule
- Chemical Formula
- C27H37N3O7S
- CAS Number
- 206361-99-1
- Unique Ingredient Identifier
- YO603Y8113
- Background
Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy. It was initially approved by the FDA in 2006.
Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to combat this infection. Clinical trials are underway and are expected to conclude in August 2020.
- Indication
Darunavir, co-administered with ritonavir, and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) in children age 3 or above and adults with HIV-1 infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2014-08-25
- Lead Sponsor
- Tibotec Pharmaceuticals, Ireland
- Target Recruit Count
- 52
- Registration Number
- NCT02187107
Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT02159352
- Locations
- 🇺🇸
Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States
Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS
- Conditions
- HIV/AIDS
- Interventions
- Drug: ART with 2 NRTIs plus LPV/r (or ATV/r)
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 120
- Registration Number
- NCT02155101
- Locations
- 🇨🇲
Yaounde Central Hospital, Yaounde, Centre, Cameroon
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT02116660
DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 42
- Registration Number
- NCT02063360
Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts
- Conditions
- HIV-1 InfectionImmunosuppression-related Infectious Disease
- Interventions
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
- Target Recruit Count
- 120
- Registration Number
- NCT01928407
- Locations
- 🇫🇷
Hopital Saint Antoine, Paris, France
🇫🇷Hopital Le Bocage, Dijon, France
🇫🇷C.H.D de Vendee, La Roche Sur Yon, France
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
- Conditions
- Human Immunodeficiency Virus Infection
- Interventions
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 37
- Registration Number
- NCT01869634
- Locations
- 🇺🇸
University of California Davis, Sacramento, California, United States
A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 8
- Registration Number
- NCT01810887
Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
- Conditions
- HIVHyperlipidemia
- Interventions
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 34
- Registration Number
- NCT01695954
- Locations
- 🇺🇸
Bellevue/NYU AIDS Clinical Trials Unit, New York, New York, United States
A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableOther: SOC adherence versus SOC+CPI adherence
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 545
- Registration Number
- NCT01641367
- Locations
- 🇧🇷
Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, RS, Brazil
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇮🇳Chennai Antiviral Research and Treatment (CART) CRS (11701), Chennai, Taramani, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.